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ABOUT THE COVER
The logo of West Allis Memorial Hospital (the.shaded area
of the design on the cover) was chosen in the late 1960’s
from the many submitted by the now defunct E. F. Schmidt
Printing Company. I put down in print, in the 1985 Cancer
Program Annual Report, the extended meaning before the
memory was lost.
The bottom half is a stylized M, which stands for Memorial
dedicated to the memory of those who served in our wars.
It is also asymbol of the broad base of community support:
the foundation, if you will upon which the hospital was
built and continues to flourish. The upper half is a W and,
with the central spire representing ãnA, stands for West
Allis. Together then, it is West Allis Memorial: But it is
more. The upper gracious concave is chalice-like, signifying
the fullness of the offering; the gift this hopitaI was meant
to be. The central spire signifies the desire for excellence
that is central to our mission.
These are the elements that are in our Cancer Program. The
broad base of support is in the community, as well as the
enthusiasm of the medical and paramedical personnel.
Nursing, dietary, rehab services, laboratory, radiology,
pharmacy, medical records, administration, volunteers, and
medical library services provide the broad base on Which

1V;JVV..

V

our search for excellence in patient care stands. The sharp
point of the spire represents the cutting edge of technology
and the constant reassessment of what constitutes
excellent care. It is this constant reassessment that is the
heart of intellectual curiosity and professionalism. Perhaps
chalicen
most important to the Cancer Program is the
awesome
the
of
appreciation
In
logo.
portion of the
problems the patient with cancer confronts, it i this that
we have to offer. Into this is poured our knowledge, our
skills, our compassion, our commitment. Let’ try to see
that this cup “runneth over”.
In 1 988 the Cancer Committee created the design for the
cover of the Annual Report which was illustrated by
hospital employee, Jeri Jende. The crab which is the
universal symbol for cancer and the sword which is
symbolic of the fight against cancer were added to the
hospital logo. This design symbolizes, in addition to the
above, the underlying commitment of West Allis Memorial
to the fight against cancer.
V

Daniel P. Collins, M.D.
Cancer Committee Chairman
1985-1992

CANCER COMMITTEE ChAIRMAN’S FOREWORD
growth in the number of patients seen and
treated at our institution. While our patient
numbers decreased slightly from our banner
year of 1 992, we have increased approximately
6% over 1991. West Allis Memorial Hospital
continues to show its strength in the delivery
of oncology-related therapy when one looks at
the diversity of patients that are treated at our
institution. All sub-categories of oncologic
therapy are delivered except those which
require an extensive technical component or are
associated with limited patient numbers (such
as bone marrow transplantation).
In this report, two major areas are highlighted.
As part of our continued accreditation by the
American College of Surgeons, we have
participated in an analysis of patients with a
diagnosis of pancreatic carcinoma. We will
introduce this topic through a series of brief
discussions by our physicians at West Allis
describing the surgical, chemotherapy, and
radiation therapy aspects of the treatment of
this disease. This will then be followed by a
report from the American College of Surgeons
on cancer of the pancreas. Additionally, this
report will also describe the rehabilitative
therapy which is available for patients with
cancer.

Kevin J. Murray, M.D., Chairman
To colleagues and friends, on behalf of the
Cancer Committee at West Allis Memorial
Hospital, I am pleased to present the 1993
Cancer Program Annual Report. This report
contains extensive information regarding our
Cancer Program at West Allis Memorial Hospital
and demonstrates that physicians and staff
continue to maintain a strong commitment to
excellence in clinical research and educational
activities. One of our educational activities, the
weekly Tumor Board, serves as a focal point for
the multidisciplinary discussion of patient care
and as a catalyst in the delivery of the new
cancer therapy.

I would like to thank all those members of the
Cancer Committee who have volunteered their
time to serve on the committee and who have
helped generate this report. I would also like to
thank all the people involved in the delivery of
oncology-related services. Their kindness and
support is constantly mentioned by the patients
and is truly deeply appreciated.

As you will see later in this report, analysis of
our tumor registry data demonstrates continued
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HVTRODUCTION
embrace the concepts of Continuous Quality
Improvement (CQI). CQI is a philosophy that
directs change and the tools necessary to meet
patient, physician and payer satisfaction. This
is a continuous journey that will never allow us
to feel comfortable with where we are and how
much we have achieved at any given time. We
are proud of this achievement.

The fight against cancer demands technology,
vision and commitment. The Cancer Program of
West Allis Memorial answers this demand. Over
the years we have seen a steady increase of
people needing our oncology services. This year
we have served an additional 880 new patients
with cancer. We answer this need proudly.
Recently we passed the stringent guidelines of
the American College of Surgeons, Commission
on Cancer designating our Cancer Program as
a Community Hospital Comprehensive Cancer
Program. This designation is the highest any
non-teaching hospital can achieve.

Excellence is our way of life, emphasizing
personalized care in the delivery of services.
People are our most important resource mani
fested by our belief in the worth, dignity, and
unique contributions of each individual. We are
here to serve others providing services that are
responsive to the needs of the community.

Our Cancer Committee is multidisciplinary and
is charged with continually monitoring the care
of cancer patients to identity possible improve
ments or enhancements to their care. This
committee and the overall Cancer Program

The purpose of this report is to inform and to
document this hospital’s experience in cancer
control activities during 1993.
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Internal Medicine

William Braunstein, M.D.

Family Practice

Mark Dorow, M.D.
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Physical Medicine
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Senior Vice President
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Ass’t Nursing Administrator
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Director of Health Information Services

Barbara Daso, R.R.A.
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CANCER COMMITTEE

Rote of the Cancer Committee

of these studies are included in another section
of this report.

The Cancer Committee is a standing committee
of the medical staff and is the coordinating and
governing body for all cancer-related activities.
The committee participates with administration
in developing goals, objectives, strategic plans,
approval and implementation of all new pro
grams as well as overseeing ongoing programs.
The committee met five times in 1993.

Tumor Registry
The committee supervises and serves as
consultant to the Tumor Registry. Committee
physicians provide quality assurance for the
staging and abstracting activities in the Tumor
Registry by routinely reviewing abstracts for
accuracy and completion.

Program Accreditation

Consultative Services
The hospital recently received three-year
accreditation of the Cancer Program by the
Commission on Cancer of the the American
College of Surgeons. The Cancer Committee
has the responsibility of assuring maintenance
of this accreditation status.

An important function of the committee is to
assure that consultative services in all
disciplines are available for all cancer patients.
Weekly Tumor Boards are conducted with this
purpose in mind. A multidisciplinary approach
to patient management is promoted at the
Tumor Boards. Tumor Boards and educational
programs are planned to cover all major cancer
sites and issues of cancer care.

Patient Care Evaluation Activities
The committee is continually monitoring the
care of the cancer patient for possible
improvements or enhancements in patient
management. The committee participated in the
American College of Surgeons long and shortterm studies on pancreatic cancer and the
special prostate cancer study of patients
treated with radical prostatectomies. One of the
obvious benefits of participating in these
studies is the ability to compare our results to
aggregate data of approved-program hospitals
nation-wide. Follow-up review was performed
of studies conducted in previous years. Review
is performed to evaluate the effectiveness of
the monitoring, evaluation and outcome
improvement activities. This year the review
included the Adriamycin, stomach cancer and
colon cancer studies. Study results are
forwarded to the appropriate medical staff
service and/or committee. Some of the results

Screening Activities
The hospital’s Mammography Screening Clinic
continued to offer low cost affordable
mammography to the community. In 1993,
5,599 persons had screening mammograms
done at the clinic. Free mammography
screening was again offered to all female
hospital employees without insurance coverage.

Community Education
Activities this year included programs for
nutritional counseling, smoking cessation,
prevention, early cancer detection and
environmental hazards. Educational cancer
related pamphlets were made available through
out the hospital.
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TUMOR BOARD
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TUMOR REGISTRY REPORT
cation and staging of cancer will allow the
physician to determine treatment more appro
priately, to evaluate results mote reliably, and
to compare, more confidently worldwide statis
tics reported from various institutions on a
local, regional, and national basis.

Computerized Data System
The Tumor Registry is a computerized informa
tion and tracking system designed for the
collection, management, and analysis of data
on patients with cancer. In 1993 the registry
converted to a new computerized registry
program, Electronic Registry Systems {ERS).
This new program comes with full capabilities
for on-line abstracting, follow-up, and reporting.
Other software programs were also installed in
the registry computer system to enhance the
reports generated by the registry staff.

In 1993, all new cancer cases were staged
utilizing the new fourth edition of the AJCC
staging manual. Staging forms are added to the
medical record at the time of patient discharge
for completion by the physician,

Lfrtime follow-up

Database

Physicians have learned that for the best care,
cancer patients require lifetime follow-up. The
Registry conducts annual lifetime follow-up of
each cancer patient. Most of our follow-up
information is obtained through hospital re
admissions and outpatient visits. Physicians are
also contacted on a regular basis, usually each
year, to inquire about the cancer status and any
subsequent treatment for their cancer patients.
Even if the patient changes physicians,
hospitals, or moves, the registry will continue
to follow the patient.

The registry documents all the significant
treatment
and
medical,
biographical,
information of patients diagnosed with cancer
and acts as a data bank for this information. All
data collected is treated with the same
confidentiality as with any medical record. The
registry contains data collected since the
official start of the registry, January 1, 1 978.
In 1 993, 880 new cancer cases were added to
the registry. A total of 10,670 cases have been
accessioned in the registry as of December 31,
1993.

A patient is considered lost-to-follow-up if
contact has not been made in the last 15
months. In order to produce meaningful survival
statistics approved cancer programs are
required to have at least a 90% follow-up rate.
Over 5,000 patients are on active follow-up
status. In 1 993 an average 94% follow-up rate
was maintained.

Cancer Staging
Approved Cancer Programs are requited to
stage cancers using the TNM staging scheme.
Devised originally by the International Union
Against Cancer, the classification was further
refined and promulgated in the United States by
the American Joint Committee on Cancer
(AJCC).

Cancer Data Reporting
Data is reported regularly to the medical and
hospital staff members. An overview of cancer
registry data is reported and published in the
Cancer Program’s Annual Report. Cancer
registry data is reported at Tumor Boards.
Physicians and hospital staff are encouraged to
utilize cancer registry data for research, grant
proposals, marketing, etc. In 1993, eighteen
requests for information were processed by
registry staff. Responses to requests for cancer
registry data are processed in a timely manner.

Cancer staging schemes are designed for
different anatomical parts, systems, or organs.
Currently, the anatomic extent of disease
provides the primary basis for staging. The
histopathologic grade and the age of the patient
are also factors in some tumors. In the future,
biologic, molecular, genetic and other prog
nostic indicators may play a part.
TNM staging is an objective assessment of the
anatomical extent of disease. Proper classifi
5
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Patient Care Evaluation Studies

American Health Information Manag
ement
Association and the Wisconsin Health
Infor
mation Management Association.
Active
membership is maintained in an effort
to keep
abreast of all the current and future change
s in
the health care information management
field,
and in particular, as it relates to cancer.

In addition to the data collection
for the
patients accessioned in the registry,
registry
personnel collected the data for the
Cancer
Committee’s patient care evaluation
studies.
Studies completed in 1993 were the long
and
short-term pancreatic cancer studies
and the
special prostate cancer study of the
American
College of Surgeons. Some of the results
of the
pancreatic cancer studies can be found
in
another portion of this report. Follow-up
studies
were also conducted for the Adriamycin
and
stomach cancer studies from previous
years.

Conferences sponsored by some of the
above
associations were attended by registry
staff.
Continuing education opportunities
are
welcomed both to raise the level of knowle
dge
and improve the performance of
registry
personnel.

Other Activities

Inquiries Welcomed

The Cancer Program Annual Report is
prepared
by registry staff with contributions
by staff
physicians, under the direction of the Cancer
Committee. The registrar serves as staff
to the
Cancer Committee and is responsible for
taking
the minutes of the Tumor Board meetin
gs.
The Tumor Registry staff are active partici
pants
in the Wisconsin Cancer Registrar’s
Assoc
iation, the
National
Cancer Registrar’s
Association, the American Cancer Society,
the

6

The registry staff welcomes inquiries
and the
opportunity to assist medical staff membe
rs to
retrieve cancer data. Requests can be
made by
calling 328-7122.
Priscilla Eckert, ART, CTR
Tumor Registrar
Sharon Miller
Follow-up Service
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CANCER PROGRAM FACILITIES
their families. Each health care discipline is
represented to facilitate continuity of care for
rehabilitation services.

Integration of Services
The Cancer Program provides continuity of all
aspects of care (e.g., inpatient and outpatient,
medical, surgical, radiation, and support). There
are appropriate data collection facilities and
follow-up procedures in place. Clinical research
protocols are available and patients are offered
the opportunity to participate in national
treatment protocols.

Support Services
Several support groups are available to the
cancer patient and their families in the hospital.
They are I Can Cope, Positive People, Living
Through Loss, and Care for the Care Giver.
I Can Cope is a patient education program
offered by the hospital in conjunction with the
American Cancer Society. Positive People is a
unique support group offered by West Allis
Memorial. Oncology nurses facilitate the
meetings to help people understand and cope
with their disease. Living Through Loss is an
information series and support group to learn
about loss and grief and ways to move beyond
loss. Care for the Care Giver is a support group
for care givers to discuss concerns, vent
frustrations and share ideas for coping. Con
sults are arranged for breast cancer patients
with Reach for Recovery volunteers of the
American Cancer Society, when ordered by the
physician.

Oncology Unit
The oncology unit is a 30-bed dedicated unit
which was developed to adequately and
competently intervene in the complex and
unique needs of cancer patients. Qualified
oncology nurses are staffed to provide expert
assessment and intervention regarding the
disease process treatment modalities, and
symptom management. The unit provides an
ambiance of patient-centered care including
educational and support activities.

Outpatient Oncology Clink
The outpatient oncology clinic is located in
a newly constructed outpatient addition to the
hospital which was recently opened. This unit
provides convenient access to clinical labor
atory services and routine diagnostic radiologic
services while ensuring qualified and exper
ienced oncology staff to administer and manage
cytotoxic agents.

Outreach Programs
West Allis Memorial offers a number of services
to the cancer patients and the community.
Meals prepared at the hospital are delivered to
the homes of individuals who are unable to
prepare meals themselves through the Meals
Ala Wheels program. Home visit services offers
a wide variety of laboratory and diagnostic
services, 24 hours a day, 7 days a week. Other
home services which can be arranged may
include services from nursing to nutrition to
equipment and therapy. There is a mechanism
in place to inform patients and family members
of the services available.

Rehabilitation Services
Cancer is a chronic disease and therefore
requires adjustments to physical and emotional
well-being for quality of life to be maintained by
patients and their families. A variety of health
care professionals are needed to address the
rehabilitation needs of patients with cancer and
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WEST ALLIS MEMORIAL HOSPITAL
ACCESSIONS
PRIMARY SITE TABULATIONS FOR 1993
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WEST ALLIS MEMORIAL HOSPITAL
PRIMARY SITE TABULATION FOR 1993 ACCE
SSIONS

PRIMARY SITE

TOTAL

CLASS
A

SEX
N/A

STAGE

M

F

INS

LOC

REG

DISI

BEN

UNK

MALE GENITAL

168

160

8

168

0

PROSTATE

0

111

32

20
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0
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5

8
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0

TESTIS

0
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31

19

5

0

5

4

0

5

0

OTHER

0

3

0

1

0

1

1

1

0

1

0

0

0

1

0

0
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URINARY SYSTEM
BLADDER
KIDNEY/RENAL

54

48

6

41

13

20

19

4

8

35

0

30

3

5

29

6

20

10

2

1

0

19
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2

1

12

7

0

9

2

7

0
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1

0
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0
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2
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9

9
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4

5

0
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2
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0
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0

0

0

0

0

0

0

0
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15

0

4
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0
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1

0
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0

15

0

0

4

11

0

14

1

0

0

0

0

0

0

0

0

0

0

0
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PHYSICAL MEDICINE REHABIL
ITATION
By Jeffrey B. Goretwk, M.D.

a goal that is mostly related to fun
ction. People
who experience cancer, whether
they undergo
surgery or not, can often times hav
e secondary
problems with swelling, decreas
ed motion of a
particular joint, difficulty bath
ing, dressing,
performing normal hygiene skill
s, and difficulty
ambulating. Head and neck cancer
can lead to
speech and cognitive deficits.
All of these
deficits can be treated in a formal
rehabilitation
program utilizing physical therapy,
occupational
therapy and speech pathology. The
se functional
limitations can often times be ame
liorated and
occasionally resolved. Rehabil
itation services
enhance the quality of life of tho
se who live
with cancer and allows them to
function at a
higher level. Physical medicine
and rehabil
itation approaches can also help
treat pain as it
relates to the diagnosis of cancer.
Pain can be
a functionally limiting and impairing
feature that
if ameliorated or improved conside
rably, can
allow people again to enhance thei
r ability to
function in a day-to-day acti
vity. Utilizing
different rehabilitation approache
s can allow
pain to be successfully treated wit
h a non-drug
approach.

Jeffrey B. Gorelick, M.D.
Physical medicine rehabilitation is
a discipline of
medicine that deals with physica
l disability.
The field itself was in its infancy
in the 1940’s
when veterans returning from Wor
ld War II had
ongoing disabilities. The field exp
anded drama
tically since then, grown in over
10 fold to
meet the needs of those ind
ividuals with
physical disability. Physical disa
bilities can be
associated with any diagnos
es, including
cancer. The approach physical med
icine rehabil
itation utilizes to treat individuals
with cancer is

In the past decade, as physical med
icine reha
bilitation has gotten more involv
ed in treating
individuals with cancer, strides hav
e been made
in improving people’s quality of
life. These
approaches need to be strongl
y considered
when those with cancer live day
-to-day with
impairment and/or pain.
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BREAST CANCER AND REH4BILITATION
By Linda J. Barrows, M.D.
.1
therapy, chemotherapy and hormonal therapy,
often in combination. The individual treatment
options will depend on factors such as location,
size, and type of tumor, involvement of axillary
lymph nodes, presence of other metastases, as
well as general health and patient preferences.
Previously, the Halstead radical mastectomy
was a common surgical procedure, involving
the resection of the entire breast, the axillary
lymph nodes and the chest muscles under the
breast. This left a more cosmetic deformity and
also had a higher rate of postoperative lymphedema and shoulder problems.
Newer breast conserving techniques have been
developed, including the modified radical
mastectomy. This lessens the risk of lymphedema and spares at least one of the pectoral
muscles, allowing the arm to remain stronger.
Other options include the simple {total) mastec
tomy, partial (segmental) mastectomy and lum
pectomy. These are more frequently performed
and are often combined with additional radia
tion therapy. Also breast reconstruction may be
done at the time of surgery or at a later time.

Linda J. Barrows, M.D.
INTRODUCTION

Approximately 10% of women in the United
States will eventually develop breast cancer.
According to the latest statistics of the
American Cancer Society, in 1 994 an estimated
182,000 new cases of breast cancer will be
diagnosed in women and 1,000 cases in men.
Breast cancer is currently the second leading
cause of cancer deaths among women.

POST-MASTECTOMY REHABILITATION

The total postoperative recovery time may
differ according to patient variables and type of
treatment. Patients may be discharged within
48 hours after breast cancer surgery, and often
with drains to be removed in the surgeon’s
office. There exists a need for early education
and an effective exercise training program prior
to discharge. If early discharge or patient
anxiety interferes with learning, an outpatient
session may prove beneficial.

Some of the risk factors for breast cancer
include age, personal or family history of breast
cancer, nulliparity or late age at first live birth,
early age of menarche, and late age at meno
pause. The role of dietary fat is also being
investigated. Since adult women can do little to
alter their risk, early detection can have a
significant impact on the type and extent of
treatment required. Early detection is enhanced
through a combination of regular breast self
examination, clinical physician examination and
mammography. With localized breast cancer
the estimated 5 year survival has now risen to

Lengthy therapy programs are less often
necessary now with early education and inter
ventions and more conservative surgeries.
Patients with more extensive surgeries,
including the removal of the pectoral muscles,
extensive dissection of the axilla and removal
of lymph nodes, and those with the addition of
radiation therapy are at a higher risk of shoulder

93%.
Surgery is often a first treatment of choice.
Other common treatments include radiation
13
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complications. Currently patients may be seen
for therapy as early as the first postoperative
day. The history is reviewed for previous
medical history and functional status (including
any preexisting shoulder problems), the type
and extent of surgery, as well as the extent of
social support which can be provided.
Everyone involved needs to be sensitive to the
anxiety the patient faces while waiting for the
final pathology report. There also may be a fear
of movement causing pain or injury. Adjusting
to the loss of one’s breast and change in body
image may also take time. The patient is there
fore reassured of the purpose of the evaluation
and exercise teaching, and advised that it is to
be gradually progressed at home. The patient is
also provided with an opportunity to request
additonal functional information, such as the
anticipated progression of postoperative
shoulder recovery or the effects of treatment
on lifestyle.
The patient may benefit from advice on how to
compensate for appearance until a permanent
prosthesis is allowed. The Reach to Recovery
volunteer from American Cancer Society can
supply a temporary light prosthesis which can
be pinned under clothing.

Shoulder mobilization is begun when allowed
by the surgeon. This may be as early as the
first or second postoperative day, or after the
drain is removed. There have been conflicting
reports regarding the pros and cons of early
postoperative exercises. Some of the recent
studies have shown no significantly increased
drainage or wound complications with early
postoperative exercises. Early exercises are
generally done with restrictions to stay within
the pain barrier. Initially shoulder abduction and
fiexion are purposefully restricted.
Resistive exercises are avoided until drains are
removed. Exercises are progressively upgraded
to avoid glenohumeral joint capsular changes.
Progressive active exercises and stretchin
g
gradually are allowed to become more vigorous.
Stretching is required for longer periods in
those undergoing additional radiation therapy.
Patients are reinforced to follow the surgeons
driving and lifting precautions, which can vary
according to the procedure.
It has been suggested to approach lymphedema
education judiciously, and some surgeons have
expressed concerns that this may unnecessarily
add to fears and lifestyle restrictions. Others
feel that lymphedema is still frequent enough to
warrant a thorough discussion of the precau
tions. The patient should also be informed that
the current more conservative surgical proce
dures have lessened the incidence of lymphedema and reassured that there is treatmen
t
available. Patients are instructed to notify their
physician when arm swelling occurs after dis
charge.

The characteristics of pain complaints are
recorded. Information is provided regarding
positioning techniques and to avoid incisional
stretch pain or any initial sharp pain with
exercise. Without education, one may uninten
tionally exercise too vigorously, especially
when pain is well controlled with medications.
A sensory evaluation is performed as there may
be numbness of the axilla and medial upper
arm. This may subside or become less notice
able with time.

The initial postoperative swelling in the arm will
generally resolve. Proper positioning, such as
elevation on pillow may control swelling and
increase comfort. Early lymphedema is treated
by elevation and mild compressive garments to
prevent progression. Antibiotics are used if
there is a concern with infection. The initial
compression garments used may be a tubular
garment or ACE wrap, and later an off-the-shelf
or custom garment can be prescribed. Manual
lymph drainage and retrograde massage may
later be added to help return excess fluids to
circulation. These techniques can be taught to
the patient and family members. When there
are no contraindications, more resistant or
chronic cases may be treated with the addition

A postural evaluation of the head, neck,
scapula and shoulder is important, as postural
deviations may be used to compensate for
breast weight loss and altered shoulder
function. The opposite arm is evaluated for
comparison of shoulder range of motion and
used to demonstrate how to advance exercises
properly as their healing allows. Postoperative
exercise training may prevent future pain
complaints related to shoulder girdle muscle
imbalance, residual range restrictions and
compensatory postural deviations.
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To encourage independence in activities of
daily living, through discussion of problem
areas in self cares and household tasks, as well
as vocational and avocational needs where
indicated.
• To help alleviate anxieties and fears concern
ing the diagnosis and subsequent loss of a
breast and current physical limitations, by
providing education, supportive listening and
reassurance.
The patient with preexisting disability or more
advanced breast cancer may benefit from a
Physical Medicine and Rehabilitation physi
cian referral as well. There may be additional
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issues which could be further addressed by the
Rehabilitation Team. These issues may include
more formal pain management and stress
management techniques. Significant fatigue
and weakness can also be addressed by energy
conservation and work simplification principles,
as well as by providing with adaptive equip
ment. Physical therapy may be able to provide
assistance with mobility and ambulation issues.
Return to work issues can also be addressed
when necessary. Discharge planners may assist
with obtaining help within the home, such as
services through the Visiting Nurses Associa
tion. The multidisciplinary team approach can
do much to enhance quality of life for the
cancer patient and family.
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SURGERY FOR CARCiNOMA Of THE EXO
CRINE PANCREAS
By Terence Roth, M.D., FACS.
Since surgery represents the only chance for
cure, I will review the surgical therapies for
pancreatic carcinoma. The focus will be on the
exocrine pancreas.
The first successful resection of a periampullary
carcinoma in the United States was performed
by Halstad in 1898. The surgery was a local
excision and the patient died seven months
later. In 1912 the first successful resection for
ampullary carcinoma was done in two stages.
A cholecystojejunostomy and then an end-toend pancreaticoduodenostomy. In 1934, Allen
Oldfather Whipple resected an ampullary
carcinoma in two stages. A cholecystogastro
stomy and then a resection of the second and
thirØ portions of the duodenum, along with a
wedge of the pancreatic tissue that included
the tumor. Thus we learn the McBurney’s point
was actually a line and that the original Whipple
procedure was done for an ampullary carcinoma
and not a pancreatic carcinoma by reviewing
the literature. In the original operation the bile
duct was ligated and the first and fourth por
tions of the duodenum were sutured together.

Terence Roth, M.D.
The incidence of carcinoma of the pancreas has
increased during this century. There were ap
proximately 28,000 new cases diagnosed in
1 992 and 25,000 deaths were attributed to
pancreatic carcinoma. Surgical resection still
remains as the only chance for a cure. In the
best series resectability is 40% and five year
survivals approach 17 25%. However, some
series report survivals as low as 0.4%. A
review of fifteen years of data by the National
Cancer Institute shows a 3% five year survival.

There was no gastric resection or pancreatico
enteric anastomosis. The first successful pan
creaticoduodenectomy was done by Whipple
and reported in 1935. The one stage procedure
was done in 1941 by Trumble and associates
at John Hopkins. Whipple’s operation has hen
modified but nothing is particularly new. Even
Whipple had spared the pylorus in his original
operation. In 1951 the resection and reanasto
mosis of the superior mesenteric vein was re
ported by Moore. This was the procedure that
was added to the original Whipple operation.

-

The causes of pancreatic cancer remain
unknown. However, several risk factors have
been identified. A smoker’s risk of pancreatic
cancer is 1 .5 times that of a non-smoker. High
fat diets are also implicated. A protective effect
has been associated with a vegetarian diet.
Peptic ulcer surgery has a 2 5 time increase in
the risk after 1 5
20 years following partial
gastrectomy. Diabetes mellitus in chronic
pancreatitis is associated with pancreatic
cancer. Occupational exposure has been cited.
Men are more affected than women.

Today the standard operation is the pan
creaticoduodenectomy or Whipple operation. A
total pancreatectomy is being advised by some
surgeons. However, this procedure produces a
difficult to manage diabetes and does not seem
to add to the overall survival. The pylorus
sparing part of the procedure avoids the gastric
resection and the attendant nutritional prob
lems. It does not seem to compromise survival.

-

-
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no local extension or hepatic metastases are
generally resectable. Ultrasound can demon
strate an unresectable lesion if positive lymph
nodes, liver metastases, or major blood vessel
involvement is found.

The mortality rate of the Whipple procedure
approaches 5%. There was a time when the
rates approached 50% in some series and the
operation was almost abandoned. In selected
patients with tumor less than two centimeters,
no nodal metastases, and no dissection from
blood vessels, the survival rates are up to 30
57%. Other factors that are associated with
improved survival are less blood transfused
perioperatively, absence of vascular invasion,
and tumor diploidy. The histologic factors that
are associated with poorer survival include:
malignant infiltration of the pancreatic capsule,
round cell infiltration at the margins, and
epithelial atypia in the involved pancreatic
ducts.

Intraoperative assessment is also necessary to
determine resectability. Initial dissection to
separate the superior mesenteric and portal
veins from the head and neck of the pancreas
are crucial to determine resectability. Lymph
node involvement can be determined and re
sectability is still possible if the nodes can be
dissected en bloc. A normal splenic vein allows
resection. Pancreatic biopsy should be done to
90%
confirm the diagnosis and can be 85
accurate. Liver masses should also be biopsied
for confirmation since lesions such as hamart
omas may mimic metastases.

-

-

Those patients that fail have both local and
systemic recurrent disease. About 75% is local
recurrent disease. This begs the case for a
more radical surgical procedure. However,
many studies can not demonstrate a survival
advantage of the more radical procedures.
Actually the more radical procedures offset any
theoretic advantage with an increase in opera
tive mortality and post operative morbidity
rates.

If nonresectability is found, a palliative
resection may be considered. Thirty to sixty
percent of resections are in effect palliative.
This is because tumor is left behind. The
resection of the tail could be considered even
with liver metastases if the operative mortality
can be acceptably low. This is 5 10% in some
series. However, even this is usually not
possible for cancer of the body of the pancreas.
Unfortunately this is usually a surgical exercise
in futility and its undertaking should be
considered in only the appropriate candidates.
Bypasses should be the primary consideration
in those patients that are found to be
unresectable for cure.
-

Therefore, any future developments will not be
in the area of more radical surgery but in earlier
diagnosis, risk assessment, and improved ad
juvant therapies.
The surgeries themselves are associated with
several complications. These include: intestinal
obstruction, hemorrhage, intra-abdominal
abscess, fistula, anastomotic complications,
wound infections, wound dehiscence, septi
cemia, and endocrine and exocrine pancreatic
insufficiency.

Relief of biliary obstruction should be consider
ed when possible. However, jaundiced patients
20% mortality and a 40 60%
have a 15
the first consideration
Therefore,
morbidity.
jaundice with either an
the
relieve
to
be
should
endoscopically or percutaneously placed stent.
This may not be possible and therefore other
procedures should be considered. The most
common is cholecystojejunostomy. Cholecysto
jejunostomy should also be considered as pre
sumably a better diversion procedure. Some
prefer the choledocho- or cholecystoduoden
ostomy. The involvement of the duodenum
later may not make these procedures the best
choice. Cholecystogastrostomy is another pro
cedure to be used. However, the bile gastritis
may preclude this operation as the one of
choice.
-

-

Before resective surgery can be performed, an
assessment of resectability must be done. This
is done on a clinical basis and intraoperatively.
Clinically back pain is an ominous sign. About
25% of patients have it at presentation. In one
series 29 of 33 patients were not resectable
when they had a presenting complaint of back
pain. If the lesion is in the body or tail, 56%
having this finding preoperatively, none were
resectable. Other physical signs connected with
nonresectablility are; cervical adenopathy,
ascites, rectal shelf, and an umbilical nodule
(the Sister Mary Joseph sign). CT findings of
19

Relief of duodenal obstruction is another con
sideration. Nausea and vomiting are present in
30 45% of patients with pancreatic cancer.
Actual obstruction occurs in only 5% of
patients. Tumors of the head obstruct the
second portion of the duodenum and may result
in jaundice. Tumors in the head and neck may
also obstruct the pancreatic duct. If a patient
only undergoes the biliary bypass, 1 7% will
develop duodenal obstruction within 8
9
months after the operation. The mortality rate
of the second operation has been reported to
be between 6 100%. Delayed gastric empty
ing may occur after duodenal bypass and upper
gastrointestinal bleeding can occur after the
double bypass. However, they are usually
treated by conservative measures and quite
successfully.

reflux, dumping, and diarrhea is lower than
with the classic Whipple operation. The pro
cedure can be considered for curative and
palliative resections. This procedure does not
compromise long-term survival in malignant
disease.

-

Pancreatic cancer has been treated with partial
and total pancreatic resection. Total pancreat
ectomy was advocated in the past. It was felt
to be superior to partial pancreatectomy be
cause of concerns regarding tumor involvement
of any remaining pancreas and anastomotic
problems such as obstruction and fistula. There
has been little if any support for total pan
createctomy recently. One must be always
mindful of the diabetes caused by total pan
createctomy as it can be difficult to manage or
life threatening.

-

-

Pain may be present in 70 90% of patients
with pancreatic cancer. Pain in the back is a
characteristic of cancer of the body and tail of
the pancreas. The greater the pain that is
present the less that can be done surgically to
resect the tumor. Pancreatic duct decompres
sion into the stomach with a T-tube can be a
consideration if the obstruction can be demon
strated. Another way to do it is to place a
pancreatic stent endoscopically or percuta
neously. Chemical ablation of the celiac ganglia
is an option. Chemical splanchnicectomy has
given relief. The pain can also be treated with
the addition of external beam therapy if the
above fail or as a primary therapy. A percuta
neous celiac block can also be done and is
repeatable at a later date.
-

A few words about the extended pancreatico
duodenectomy are in order. This is done to
include the various nodal pathways that the
tumor can follow. Celiac, splenic, portal,
choledochal, superior mesenteric, aortic, and
vena caval nodes are included in the resection.
The operative mortality can be acceptable as
one gains experience. This procedure may be
most helpful in early, small, localized tumors.
However, this usually represents fewer than
5% of patients and over half of them already
have nodal metastases.
In conclusion, surgery is the only real chance
the patient has for a cure. After resectability
has been determined, an extended pancreatico
duodenectomy should be considered with the
pylorus sparing procedure being included. Pain
therapy should be started with some sort of
nerve block. In the future improvement of
adjuvant therapies should improve survival. The
long-term hope is that earlier diagnosis pro
cedures would be developed. Risk factors need
to be identified and molecular biology including
genetics will become important. Considerable
amounts of time and resources will be neces
sary if any significant improvement in the treat
ment of carcinoma of the pancreas is to be
accomplished.

Other considerations in pancreatic surgery
including IORT (Intraoperative Radiation Ther
apy should be covered elsewhere in the report.
A few words about pylorus preserving pan
creaticoduodenectomy: it can be done with a
low operative mortality and morbidity, is faster
to do than the standard Whipple operation,
reduces the incidence of marginal ulceration
after pancreatectomy, minimizes the long-term
physiological disturbance to the patient. Gastric
emptying may be prolonged transiently but it is
easily treated. The incidence of enterogastric
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RADL4 TION THERAPY FOR PANCREATIC CARCINOMA
By Kevin Murray, M.D.
then recommended for patients with a pancre
atic mass so that:
1. A biopsy of this mass can be made
and a diagnosis made
2. If feasible, a total excision of this
mass can be performed
3. If not surgically resectable, a divert
ing procedure can be performed to
improve the drainage from the gall
bladder and liver.
Following the surgical procedure, there are two
main rationales for delivering postoperative
external beam irradiation. The first is that in
patients who are deemed to be unresectabje,
local external beam radiation may cause signifi
cant tumor shrinkage and relief of their
debilitating symptoms. The second is that,
except for patients who present with an
extremely small (less than 1 cm.) lesion of the
pancreas, there remains a substantial risk of
local regional failure in patients following
surgery. Postoperative external beam radiation
generally in conjunction with systemic chemo
therapy is used to decrease this rate of failure.
An important study demonstrating the value of
combined modality therapy was performed by
the Gastrointestinal Tumor Study Group in the
early 1980’s. This group randomized 157
patients following potentially curative resection
of pancreatic carcinoma to receive 5-FU chemo
therapy and 40 Gy external beam irradiation
versus no further treatment. The survival at one
year was only 49% for patients who had no
further therapy versus 63% for the treated
patients. This difference is even more striking
at two years where only 15% of the control
patients were alive versus 42% for treated
patients.

Kevin Murray, M.D.
The pancreas, a small organ located in the
upper abdomen, is intimately associated with
digestion and helps, through its production of
insulin, control the level of sugar within the
blood. The pancreas is immediately adjacent to
major structures including the aorta, superior
mesenteric artery, stomach, duodenum and
liver. There is no actual capsule surrounding the
pancreas which therefore makes it quite easy
for cancers to invade all of these adjacent
structures.
As shown in our review of patients with
pancreatic carcinoma at West Allis Memorial
Hospital (see tables later in this book), the most
frequent symptoms are pain, indigestion, a
weight loss of greater than 10 lbs. and
jaundice. This latter problem is secondary to
obstruction of bile outflow from the liver and
the gallbladder.

Unfortunately, the long-term outlook for
patients with this disease is poor. Because of
the poor results alternative strategies continue
to be developed to combat this disease. While
this focuses mainly on developing more effec

Following presentation, the patients will
undergo a work-up generally consisting of
ultrasonography of the upper abdomen and CT
scan of the abdomen. Surgical exploration is
21
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tive chemotherapy agents, other radiation
modalities have been considered. One possi
bility is the implantation of radioactive ma
terials, such as Iodine 1 25, directly within the
tumor bed. This has been combined with exter
nal beam radiation as well as with systemic
chemotherapy and does seem to show a very
modest imptovement in median survivals for

those patients with small and well localized
lesions. Another technique, intraoperative
radiation, delivers a single large exposure of
radiation to surgically exposed tumor. While
some patients have had an excellent response
to this therapy, the majority of patients still
however recur both locally or within the pen
toneal cavity.
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CHEMOThERAPY FOR PANCREATIC CARCiNOMA
By Robert F. Taylor, MI).
postulated, but none of these have been
definitely identified as an independent risk
factor.
Chemotherapy for pancreatic carcinoma has
been available for some time, and a variety of
agents have shown some activity in the
disease. Perhaps the most widely studied agent
is 5-Fluorouracil t5-FU). Single agent studies of
5-FU have shown response rates in metastatic
disease between 5% and 20%, although few
long-term survivors have been reported in the
literature. Combination chemotherapy regimens
have also been studied, adding agents such as
Mitomycin-C, Streptozotocin, Ifosfamide and
Adriamycin to 5-EU. However, a careful anal
ysis with patients with metastatic disease,
treated in this manner, suggests that the
results of combination chemotherapy trials are
probably no higher than those treated with 5FU alone. Unfortunately, many of these studies
suffer from the disadvantage of involving a
relatively small number of patients, and a
pathologically diverse group of subjects.

Robert F. Taylor, M.D.
Cancer of the pancreas is the fourth largest
killer of adults in the United States. This
disease will affect approximately 25,000 new
cases each year in the United States, and it
remains a difficult tumor to diagnose and treat
early. The highest cure rates in cancer of the
pancreas are in those patients who have truly
localized disease. Unfortunately, only about
20% of patients have disease that is localized
and even in those patients, when they are
treated with surgical resection alone, cures
occur in less that 5% of all patients. For small
cancers in the head of the pancreas with no
lymph node metastases and no extension
beyond the capsule of the pancreas, survival
rate approaches 20% but still remains a signifi
cant problem.

It appears that most pancreatic carcinomas
express multi-drug resistance phenotypes,
which makes them relatively insensitive to
many chemotherapy agents. Anthracyclines,
such as Adriamycin, can be effective in
patients expressing a multi-drug resistant
tMDR) positive tumor, and some of these are
being investigated. A new agent, Gemcitabine,
is being evaluated in pancreatic carcinoma for
its abilities to exploit the MDR characteristics of
this tumor.
Another area of interest in the development of
chemotherapy agents involves the modulation
of 5-FU. One popular agent in this regard is
Leucovorin (Leucovorin Calcium). Addition of
Leucovorin to 5-Fluorouracil is thought to
intensify the inhibition of thymidylate synthase
and potentiate the activity of 5-Fluorouracil.
Unfortunately, clinically significant improve
ments with the addition of Leucovorin have not
been conclusively demonstrated in series
reported to date. Other agents felt to biochemi
cally modulate 5-EU include Pala and Metho
trexate. Unfortunately, none of these drug

The reason for the rising incidence of pan
creatic carcinoma in the United States is
uncertain. Several environmental factors have
been associated with an increased risk of
pancreatic carcinoma but none have been
identified as specifically causative. An assoc
iation between alcohol consumption, cigarette
smoking and coffee drinking have all been
23

combinations has demonstrated substantial
improvement in survival or response rate over
5-Fluorouracil alone. Differences in dosing
schedules and timing of chemotherapy may be
beneficial in studies of this tumor, but as yet
none of the available studies are conclusive.

This appears to be accomplished without sub
stantial increase in morbidity or mortality.
Whether the addition of other agents such as
Adriamycin, Streptozotocin or Mitoxantrone to
5-FU add substantially to the effect of 5-FU on
patients undergoing radiation therapy, has not
yet been proven.

Perhaps the most useful adjunct for chemo
therapy, in patients with pancreatic carcinoma,
is the use of chemotherapeutic agents, partic
ularly 5-FU, in combination with radiation
therapy. Several studies have suggested that 5Fluorouracil acts as a radiation sensitizer for
tumors of the gastrointestinal tract, and several
investigators have evaluated the effects of 5Fluorouracil when combined with radiation ther
apy for pancreas patients. The most promising
data involves those patients who have under
gone a complete surgical resection of their
primary, but who remain at substantial risk
because of the extensiveness of their tumor or
the microscopic involvement of regional lymph
nodes. In patients such as this, the additiàn of
5-Fluorouracil to local radiation therapy has
been reported to improve both local control and
long-term disease free survival in such patients.

Clearly, pancreatic carcinoma remains a diffi
cult tumor to treat, and new approaches and
new drugs will be necessary. Many studies
investigating the exploitation of multi-agent
resistance gene therapy are underway (not only
in this tumor but in others) and, if fruitful, they
may prove to be quite useful if not curative in
this difficult disease. Obviously, early detection
remains a major stumbling block in the effective
use of chemotherapy, radiation therapy or
surgery in this disease and, despite the advent
of newer radiographic and endoscopic tech
niques, early detection of this tumor remains
elusive. Further investigations of environmental
carcinogens and other risk factors may prove
useful in reducing the incidence of this cancer
and may ultimately prove to be the most useful
therapeutic intervention of all.
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AMERICAN COLLEGE Of SURGEONS
PA TIENT CARE EVALUATION STUDIES
CANCER Of THE PANCREAS
clinical evidence of a primary tumor of the pan
creas have been included.

Purposes of the Stttdies
These studies of pancreatic cancer were
conducted to document the current methods of
diagnosis, staging, and treatment. Each partic
ipating hospital can compare its data to the
aggregate data of all the other participating
hospitals. The information from these studies
may lead to higher quality of patient care.

Types of Cases Entered
Patients admitted for all or part of their first
course of therapy were entered in the studies.
This includes patients diagnosed at our facility
who refused therapy and patients who were
untreatable for any reason. If part of the first
course of therapy was administered in another
hospital, this hospital must have administered
the most definitive part of the first course of
therapy. The patient may or may not have been
diagnosed at this facility. The 1985 study
contains 13 cases that met the eligibility
criteria. The 1990 study contains 6 cases.

Eligibility of Cases
Cases entered into the studies must have a
histologically confirmed primary cancer of the
pancreas. If biopsy of the pancreas was not
obtainable, patients that have been diagnosed
with histologically proven metastasis, having

PANCREATIC CANCER
PRIMARY SITE

TAIL OF PANCREAS
33%

OVERLAPPING LESIONS
46%

OVERLAPPING LESIONS
17%

1985 STUDY

-

BODY OF PANCREAS
23%

BODY OF PANCREAS
17%

•HEAD OF PANCREAS
31%

HEAD OF PANCREAS
33%

WAMH

1990 STUDY

-

WAMH

*
OVERLAPPING LESIONS ARE TUMORS WHICH EXTEND OVER 2 OR MORE SUBSITES AND IT IS NOT POSSIBLE TO TELL
WHERE THE TUMOR ORIGINATED
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PANCREATIC CANCER
PATIENT SMOKING HISTORY

YES

YES

UNKNOWN
NO

1985 STUDY

-

WAMH

1985 STUDY

NATIONAL

-

YES

YES
50%

50%

JKNOWN
NO

NO

1990 STUDY

-

WAMH

1990 STUDY

-

NATIONAL

According to the American Cancer Society
incidence is more than twice as high for
smokers as nonsmokers. In the graphs above,
WAMH appeared to have over 20 percent more

Primary Site
The subsite of the pancreas where the tumor
started could not be determined with large
tumors (overlapping lesions) because definitive
surgery was not performed. In some cases a
needle aspirate of the pancreas or metastatic
site was the only invasive diagnostic procedure.

smokers in the 1 985 study than the rest of the
hospitals in the study. The 1 990 study showed
both groups with about one-half of the patients

with a smoking history. Of note are the sizable
unknown portions of the national group for
both study years. This probably means WAMH
had better documentation of smoking history.

Risk factor
Smoking is a risk factor for pancreatic cancer.
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PANCREATIC CANCER
PATIENT AGE

—NlNETIES
..

1%

>

12%

—EIGHTIES

—SEVENTIES
SEVENTIES

SIXTIES

31%

23%

—SIXTIES

32%

—FIFTIES

16%

46%

—

FIFTIES

8%

—<

FIFTY

7%

1985 STUDY-NATIONAL

1985 STUDY-WAMH

—NINETIES
I—EIGHTIES
SEVENTIES

1%

>

13%

33%
32%

SIXTIES

33%
32%

FIFTIES

1990 STUDY-WAMH

33%

1990 STUDY-NATIONAL
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fPANCREATIC CANCER STUDIES

SYMPTOMS PRESENT

SYMPTOMS
ABDOMINAL PAIN

177

I 83

117

BACK PAIN

39

I 83

INDIGESTION

154:
150

.IALJNflIflI

46

PRURITIS

I

17
15

117

RECENT ONSET DIABETES

15
50

WEIGHT LOSS >10 LBS.

154:

0
OTHER
0
0

40

20

60

80

100

PERCENTAGE

L1199o

STUDY-WAMH D1985 STUDY-WAMH

Incidence

Symptoms at Diagnosis

There were an estimated 27,700 new cases of
pancreatic cancer in the United States in 1993.
According to the American Cancer Society, the
risk of cancer of the pancreas increases after
the age of 50, with the most cases occurring
between the ages of 65 and 79. This fact was
confirmed in the studies, as noted in the graphs
on the opposite page.

are
symptoms
predominant initial
The
abdominal pain, indigestion, jaundice, and
weight loss over 10 pounds. Unfortunately,
cancer of the pancreas is a “silent” disease,
one that occurs without symptoms until it is in
advanced stages.
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PANCREATIC CANCER STUDIES

DIAGNOSTIC WORK-UP PERFORMED

DIAGNOSTIC PROCEDURE
77

ABO. ULTRASOUND

100

ANGIOGRAPHY

8

BONE SCAN
BRAIN SCAN1

15
0

CEA (PREOPERATIVE)

50:
92

CT SCAN OF ABDOMEN
CHEST X-RAY

100
85
--.
-----

ERCP*1
LIVER SCAN

23
17

67

54
33

:

PTC**8
.77

UGI, BARIUM
OTHER1
40

60

80

100

120

PERCENTAGE OF CASES

\

•1985-WAMH 1Th990-WAMH
*
**

Endoscopic Retrograde Cholangiopancreatography
Percutaneous Transhepatic Cholangiography
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PANCREATIC CANCER STUDIES
FIRST COURSE OF TREATMENT

SURGERY

-

TYPE OF SURGERY
J-

BIOPSY OF OTHER SITE

I

50

23

BIOPSY OF PRIMARY SITE

17
0

BYPASS SURGERY

17

131

BYPASS W/BIOPSY
17.

115

PARTIAL PANCREATECTOMY

0

PANCREAS W/GASTRECTOMY

0
0

10

20

30

40

50

60

PERCENTAGE

El 1985 STUDY
*

-

WAMH El 1990 STUDY

-

WAMH

PANCREAS W/GASTRECTOMY MAY BE A DUODENECTOMY W/PARTIAL OR COMPLETE PANCREATECTOMY

Diagnostic Work-up

Surgical Treatment

Abdominal ultrasound and CT scan of the
abdomen were used for all the diagnostic workups in the 1990 study at WAMH. These
procedures and the endoscopic cannulation of
the pancreatic duct tERCP) were the most
useful diagnostic procedures. CT scans
suggested cancer in about 70% of the cases,
ultrasound studies in about 50% of the cases,
and ERCP in about 30% of the cases at
WAM H.

Partial pancreatectomy was the most common
cancer-directed operation (15%) followed by
pancreaticoduodenectomy (8%) in the 1985
study. There was no definitive surgery
performed in the 1990 study, only bypass
surgery. The most frequent procedures were
diagnostic biopsies. This was due to the fact
that, at the time of diagnosis, there was ad
vanced stage inoperable cancer.

30

PANCREATIC CANCER STUDIES
FIRST COURSE OF TREATMENT

PLANNED, NOT GIVEN
8%
NOT RECOMMENDED
38%

NOT RECOMMENDED
50%

YES
54%

YES
50%

/

1985 STUDY

-

WAMH -RADIATION TX

1990 STUDY

-

WAMH

PLANNED, NOT GIVEN
8%

-

RADIATION TX

PATIENT REFUSED
17%

NOT RECOMMENDED
54%
YES
83%
YE S
38%

1985 STUDY

-

WAMH

-

CHEMOTHERAPY

1990 STUDY

-

WAMH

-

CHEMOTHERAPY

Radiation Therapy

Chemotherapy

Radation therapy was given in approximately
50 percent of the cases in both the 1 985 and
1990 studies. This was higher than the national
study figures as they averaged around 25
percent for both study years. WAMH figures
may be inflated because of the small number of
cases in the studies.

Chemotherapy use doubled in 1990, when
compared to 1985. This is probably due, in
part, to the higher percentage of stage IV cases
in 1 990, plus the fact that no definitive surgery
was performed for that group.
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PANCREATIC CANCER STUDIES
AJCC
CLINICAL STAGE

STAGE GROUP

1985 STUDY
WAMH

1985 STUDY
NATIONAL

1990 STUDY
WAMH

1990 STUDY
NATIONAL

STAGE I

23.1%

11.6%

16.7%

14.4%

STAGE II

23.7%

7.3%

16.7%

7.1%

STAGE III

7.7%

9.6%

0.0%

9.8%

STAGE IV

46.2%

48.0%

66.7%

44.4%

UNSTAGEABLE

0.0%

23.4%

0.0%

24.2%

AJ CC
PATHOLOGICAL STAGE

STAGE GROUP

1985 STUDY
WAMH

1985 STUDY
NATIONAL

1990 STUDY
WAMH

1990 STUDY
NATIONAL

STAGE I

7.7%

4.9%

0.0%

5.6%

STAGE II

7.7%

1.5%

0.0%

1.5%

STAGE III

0.0%

4.8%

0.0%

6.5%

STAGE IV

0.0%

9.2%

0.0%

8.3%

UNSTAGEABLE

84.6%

79.5%

100.0%

78.2%

Clinical Stages

Pathological Stages

Most of the patients in both studies were
clinically staged. Those unstageable cases were
most likely advanced stage cases and a staging
work-up was refused. The majority of the cases
were stage IV in both the WAMH and national
categories.

The majority of the cases in both studies were
unstageable because definitive surgery was not
performed. This is because the patients were
not surgical candidates because of the ad
vanced stages of their tumors.
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PANCREATIC CANCER STUDIES
FIRST RECURRENCE

RECURRENCE TYPE

LOCAL

REGIONAL

Z17.7:
DISTANT
1.76.9
NEVER DISEASE FREE

j 85.6
80.8

NO RECURRENCE
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OTHER
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40

20

80

60

100

PERCENT

Li 1985

STUDY

EH985

STUDY

-

-

WAMH

Lii 990

STUDY

NATIONAL M1990 STUDY
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WAMH
NATIONAL
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PANCREATIC CANCER STUDIES
FIVE YEAR SURVIVAL

PERCENT SURVIVING
120
100
80
60
40
20
0
STUDY 1985
STUDY 1985

-

-

0

1

2

3

WAMH

100

46

23

NATIONAL

100

17

7

4

5

8

0

0

4

3

2

NUMBER OF YEARS
N

STUDY 1985- WAMH ± STUDY 1985

-

NATIONAL

five Year Survival

fiict Recurrence

The five year survival results for WAMH are
very favorable when compared to the national
survival rates. The survival rate for WAMH
patients is well above the national study rate,
particularly for the first two years.

The majority of the patients (76.9% 100%)
in both studies were never disease free. A small
percentage of the patients had a recurrence.
Even though WAMH had a small number of
patients in these studies, these statistics are
comparable to the national percentages.
-
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GLOSSARY

Accessioned

Entered into the Tumor Registry data base

ACOS

American College of Surgeons In 1 932 the American Cancer Society
urged the American College of Surgeons to take the lead in setting
guidelines for cancer care. Approval of hospital-based cancer programs
has been the foundation for improving the quality of care of patients
with cancer.

ACS

American Cancer Society

AJCC

American Joint Committee on Cancer
end results reporting

First Course of Therapy

First course of therapy is treatment planned and/or administered within
the first four months following cancer diagnosis in order to modify,
control, remove or destroy proliferating cancer tissue.

Hormonal Treatment

Includes administration of hormones, steroids and endocrine surgery to
control cancer

NCI

National Cancer Institute

PCE’s

Evaluation of cancer patient care
Patient care evaluation studies
problem analysis, action
problem
identification,
through the process of
planning and follow-up monitoring

SEER

Surveillance, Epidemiology and End Results program of National Cancer
Institute

Stage of Disease

The extent of disease determined at the time of initial work-up for the
first course of treatment

Subsequent Therapy

Change in treatment due to apparent failure of the original, planned or
administered treatment or because of progression of disease, such
treatment is excluded from the first course of therapy and considered
as part of a second or subsequent course of therapy.

TNM Staging

AJCC classification to determine the extent of disease at the time of
diagnostic work-up for the first course of treatment
T Size of Tumor
N Lymph node involvement
M Metastasis at distant sites

-

-

organized for cancer staging and

-

-

-

-
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